Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into definitive agreements with certain institutional investors to sell an aggregate of (i) 5,050,808 American Depositary Shares (the “Depositary Shares”) (each Depositary Share representing 400 of the Company’s ordinary shares, nominal value £0.001 per share) and (ii) 278,975 pre-funded warrants exercisable for Depositary Shares, at a purchase price of $0.94 per Depositary Share (or $0.9399 per pre-funded warrant) in a registered direct offering. Read more here: https://lnkd.in/eEKdgWdA

This #GBMDay, we would once again like to honour and stand together with all patients impacted by this cruel disease. Our team at Biodexa Pharmaceuticals PLC remains fully committed to supporting and developing new treatments to improve outcomes for patients. #GlioblastomaAwarenessDay #Glioblastoma #Biodexa #cancerawareness #braincancer

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024. After Only Two Infusions and Two Patients at Optimal Dose, Median Overall Survival Across all Patients was 16.5 Months (vs 10.0 Months in Historical Reference Cohort) #MTX110 #panobinostat #tumor #tumour #brain #DMG read more here https://lnkd.in/e-4fn85H

Biodexa Pharmaceuticals is looking for an additional Director of Clinical Operations to join their expanding team. The permanent position is full time, UK home-based with a requirement to travel to the office in Cardiff, Wales, every 4-6 weeks, and travel domestically/Internationally as necessary to support the development activities. The Director of Clinical Operations will provide functional leadership and study management/oversight of studies in an orphan indication. The role reports to the Head of Clinical Operations and will need to work closely with key stakeholders and development partners. Candidates must have global, phase III experience. If interested, please read full job description and requirements on our website. No recruitment agencies please. #hiring #job #clinical https://lnkd.in/eRYNUxNE

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) https://lnkd.in/edG6mKN6 #Biotech #Cardiff #cancer #Texas #clinicalstudy #biodexapharmaceuticals Cancer Prevention and Research Institute of Texas Cleveland Clinic

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona bit.ly/3Rn4e5f

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises https://lnkd.in/dk4Z8URk #biodexapharma #fundraise #Familialadenomatouspolyposis #T1D #glioblastoma

We are pleased to announce that results of a Phase 2 clinical trial of eRapa™ in Familial Adenomatous Polyposis (“FAP”) (NCT04230499) are scheduled for presentation at the prestigious 2024 Digestive Disease Week annual meeting in Washington D.C.. Carol Burke, MD, the Principal Investigator, will present the six month data in a podium presentation at the meeting. The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069. See the full announcement here: https://lnkd.in/eWJtZn4Y #Biodexa #BiodexaPharmaceuticals #FamilialAdenomatousPolyposis #FAP #clinicaltrials #DDW #DigestiveDiseaseWeek #eRapa #CancerPrevention

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting bit.ly/3UT8Rou

Biodexa Pharmaceuticals is looking for a Director of Regulatory Science.   The permanent position is Full/ Part-time (4-5 days/week), UK home-based with a requirement to travel to the office in Cardiff, Wales every 4-6 weeks and travel domestically/Internationally as necessary to support development activities.   The Director of Regulatory Science will lead the development and execution of global regulatory activities across Biodexa’s development portfolio, reporting to the Chief Medical Officer. Responsible for the planning and implementation of regulatory activities to assist in expeditious development of products whilst maintaining regulatory compliance.   Further information and skills required can be found here: https://lnkd.in/eUNpjGkW No recruitment consultants or agencies please. Apply with your CV and covering letter to careers@biodexapharma.com #regulatory #job #Cardiff #biotechnology #Biodexa